Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Forum for Health Economics & Policy
|
August 18, 2019
The Option Value of Innovation
Julia Thornton Snider, John A Romley, William B Vogt, et al.
Law and Human Behavior
|
February 29, 2000
Expert approaches to communicating violence risk
K Heilbrun, M L O'Neill, L K Strohman, et al.
Nature
|
November 24, 1977
Non-random chromosome gains in human lymphoblastoid cell lines
C M Steel, M A Woodward, C Davidson, et al.
Nature Reviews. Drug Discovery
|
July 30, 2005
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
Ernst R Berndt, Adrian H B Gottschalk, Tomas J Philipson, et al.
Health Economics
|
January 22, 2014
Response to Epstein's comment on "heterogeneity in action"
Anirban Basu, Anupam B Jena, Dana P Goldman, et al.
Health Economics
|
October 15, 2013
Heterogeneity in action: the role of passive personalization in comparative effectiveness research
Anirban Basu, Anupam B Jena, Dana P Goldman, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
October 1, 1995
Informed consent for research: a study to evaluate readability and processability to effect change
S J Philipson, M A Doyle, S G Gabram, et al.
The American Journal of Managed Care
|
March 2, 2013
Impact of oral nutritional supplementation on hospital outcomes
Thomas J Philipson, Julia Thornton Snider, Darius N Lakdawalla, et al.
Health Affairs (Project Hope)
|
April 8, 2015
Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains
Darius Lakdawalla, Jason Shafrin, Claudio Lucarelli, et al.
European Journal of Clinical Pharmacology
|
October 1, 1973
Lidoflazine: double-blind trial of a new coronary vasodilator in angina pectoris
B Brantmark, N Egelius, E Fabricius, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Forum for Health Economics & Policy
|
August 18, 2019
The Option Value of Innovation
Julia Thornton Snider, John A Romley, William B Vogt, et al.
Law and Human Behavior
|
February 29, 2000
Expert approaches to communicating violence risk
K Heilbrun, M L O'Neill, L K Strohman, et al.
Nature
|
November 24, 1977
Non-random chromosome gains in human lymphoblastoid cell lines
C M Steel, M A Woodward, C Davidson, et al.
Nature Reviews. Drug Discovery
|
July 30, 2005
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
Ernst R Berndt, Adrian H B Gottschalk, Tomas J Philipson, et al.
Health Economics
|
January 22, 2014
Response to Epstein's comment on "heterogeneity in action"
Anirban Basu, Anupam B Jena, Dana P Goldman, et al.
Health Economics
|
October 15, 2013
Heterogeneity in action: the role of passive personalization in comparative effectiveness research
Anirban Basu, Anupam B Jena, Dana P Goldman, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
October 1, 1995
Informed consent for research: a study to evaluate readability and processability to effect change
S J Philipson, M A Doyle, S G Gabram, et al.
The American Journal of Managed Care
|
March 2, 2013
Impact of oral nutritional supplementation on hospital outcomes
Thomas J Philipson, Julia Thornton Snider, Darius N Lakdawalla, et al.
Health Affairs (Project Hope)
|
April 8, 2015
Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains
Darius Lakdawalla, Jason Shafrin, Claudio Lucarelli, et al.
European Journal of Clinical Pharmacology
|
October 1, 1973
Lidoflazine: double-blind trial of a new coronary vasodilator in angina pectoris
B Brantmark, N Egelius, E Fabricius, et al.
Page
of 7